Objective: To examine the impact of a diabetes renal clinic (DRC) on renal functional and metabolic indices in adults who have diabetes mellitus (DM) and chronic kidney disease (CKD). Patients and Methods: All patients evaluated at a DRC in a single tertiary referral center from January 1, 2008, to December 31, 2012, were identified. Serial renal and metabolic indices from January 1, 2004, to December 31, 2014, were recorded, and trends over time were analyzed by linear mixed-effects models. Results: A total of 200 patients who had DM and CKD were identified and subdivided into 3 categories based on presumptive CKD etiology: 43 (21.5%) with type 1 DM (T1D) only, 127 (63.5%) with type 2 DM (T2D) only, and 30 (15.0%) with DM and an additional CKD etiology. Average annual absolute (mL/min per body surface area per year) and percentage (%/year) changes, respectively, in Chronic Kidney Disease Epidemiology Collaboration estimated glomerular filtration rate before vs after first DRC attendance were: À1.59 vs À3.10 (P¼.31) and À1.22 vs À9.39 (P¼.06) for T1D; À5.64 vs À3.07 (P¼.004) and À10.88 vs À9.94 (P¼.70) for T2D; and À6.50 vs þ0.91 (P<.001) and À13.28 vs À2.29 (P¼.001) for DM with an additional CKD etiology. Glycemic control worsened in those who had T2D, whereas trends in total cholesterol levels improved in those who had T1D. Conclusion: After first DRC attendance, the absolute rate of estimated glomerular filtration rate decline remained similar for those who had T1D, but it slowed for those who had T2D or DM with additional CKD etiology. Thus, benefits of combined diabetology and nephrology consultation may vary for different diabetic subpopulations. 
D
iabetes mellitus (DM) is considered one of the primary challenges to health care delivery in the 21st century. 1 The International Diabetes Federation has estimated a global prevalence of 415 million cases of DM in 2015, with a projected rise to 592 million by 2035. 2 The increase in DM has been an important contributor to the increasing prevalence of chronic kidney disease (CKD). 3 A total of 43.9% of people who have end-stage renal disease in the United States have DM. 4 Targeted control of blood pressure and glycemia can delay the onset of diabetic kidney disease (DKD) and slow its progression. 5 Diabetes renal clinics (DRCs), in which diabetology and nephrology care are delivered simultaneously to patients who have DM and CKD, hold promise in bridging the implementation gap between guidelines and clinical practice. Longitudinal studies examining the role of DRCs have revealed a reduction in the rate of renal functional decline, but the studies have been limited to subgroups of patients who have rapidly progressing DKD and who attended DRCs serially. [6] [7] [8] [9] [10] The primary aim of the current study was to determine the impact of DRC evaluation, at a single tertiary referral center in Western Europe, on renal functional and metabolic indices before and after attendance. The DRC cohort studied was stratified into 3 subgroups according to presumptive CKD etiology: type 1 DM (T1D) alone, type 2 DM (T2D) alone, and DM with an additional etiology for CKD.
PATIENTS AND METHODS

Study Design and Setting
All adults attending the DRC at Galway University Hospital in Ireland between January 1, 2008, and December 31, 2012, were identified from clinic lists, and the dates of first attendance were recorded. Clinical and laboratory information from January 1, 2004 , to December 31, 2014, was extracted from paper and electronic medical records. The study was approved by the Galway University Hospital's Clinical Research Ethics Committee.
Diabetes Renal Clinic. The DRC at Galway University Hospital was established in 2004. Patients are jointly evaluated by a team consisting of either a consultant endocrinologist and specialist registrar in nephrology or a consultant nephrologist and specialist registrar in endocrinology. Individualized plans are agreed on for target-based control of blood pressure, glycemia, lipids, and albuminuria. Referral criteria include T1D or T2D under active management along with one or more of the following:
d Current estimated glomerular filtration rate (eGFR) between 60 and 30 mL/min per body surface area (BSA) and a trend of declining eGFR; d A trend of increasing albuminuria; d Clinical features not typical of DKD, for which kidney biopsy might be considered; and d Difficult-to-control hypertension in the setting of CKD.
On the basis of the outcome of the initial evaluation, those determined to have stable CKD are referred to the general diabetes clinic for continued follow-up; those with progressive CKD stage 3 (30-59ml/min per BSA) are retained for ongoing DRC follow-up; and those with CKD stages 4 (15-29ml/min per BSA) and 5 (15ml/min per BSA) are referred to a CKD clinic run by the nephrology department, with separate DM follow-up in the general diabetes clinic.
Participants
A total of 208 patients who attended the DRC on at least one occasion between January 1, 2008, and December 31, 2012, were identified. Of these, 3 were excluded from the analysis on the basis of inappropriate referral, 2 were excluded because they were already receiving renal replacement therapy at the time of first DRC attendance, 2 were excluded because of pregnancy during follow-up, and 1 was excluded because of underlying Wolfram syndrome. The final study cohort consisted of 200 participants who were subdivided into 3 groups based on presumptive CKD etiology: T1D alone, T2D alone, and DM with an additional CKD etiology. The additional CKD etiologies consisted of atherosclerotic renovascular disease, hypertensive nephropathy, interstitial renal disease, obstructive nephropathy, glomerulonephritis, and autosomal dominant polycystic kidney disease. Criteria used to define the presence of specific additional CKD etiologies are presented in Table 1 . Patients who did not meet these criteria were deemed to have CKD attributable to T1D or T2D alone.
Data Collection Clinical Information. Clinical information was extracted for each participant from an electronic health record for patients with DM (DIAMOND, Hicom, Woking, United Kingdom), 11 as well as from hospital discharge and outpatient records entered into medical charts. Clinical indices were assigned to a specific date. If the exact date of commencement/onset was not available (eg, prescription of certain medication classes, presence of macrovascular or nonrenal microvascular complications of DM), the indices were recorded as being either present or absent before the end of longitudinal follow-up in 2014. Results of the first renal ultrasonography, renal arterial imaging, and histopathological diagnoses obtained from kidney biopsy were recorded when present. Glomerular filtration rate was estimated using both the 4-parameter Modification of Diet in Renal Disease (MDRD) 13 and CKD-EPI formulas. 12 With the IDMS-traceable Jaffé creatinine assay, the MDRD formula included a correction factor to account for the recognized overestimation of creatinine owing to chromogens such as proteins and ketones. 14 This correction factor was removed for MDRD eGFR calculation based on creatinine values measured with the creatininase assay.
Glycated hemoglobin (HbA 1c ) was measured by high-performance liquid chromatography (A. Menarini Diagnostics). The assay was switched from alignment with the Diabetes Control and Complications Trial to International Federation of Clinical Chemistry calibration in May 2011. Electrolytes and lipid parameters were measured using conventional Roche Diagnostics assays, except for low-density lipoprotein cholesterol, which was calculated using the Friedewald equation. 15 Urinary albumin was measured on a BN II nephelometer (Siemens Medical Solutions).
Statistical Analyses
Data entry and analysis were conducted using SPSS version 22.0 for Windows (IBM). A P value of <.05 was considered statistically significant for all analyses. Baseline characteristics at index DRC visit and clinical characteristics of the cohort during followup were summarized by descriptive statistics. One-way between-groups analysis of variance and Kruskal-Wallis tests, respectively, were used to compare continuous variables that were and were not normally distributed across the CKD subgroups. Categorical variables across CKD subgroups were compared using c 2 tests. Linear mixed-effects models, incorporating subject-specific random intercepts and slopes for the time periods before and after first DRC attendance, were used to examine whether CKD subgroup-specific trajectories of laboratory indices changed after DRC attendance. Separate models were fit for MDRD and CKD-EPI eGFR, log-transformed MDRD and CKD-EPI eGFR, urine albumin to creatinine ratio, glycated hemoglobin (HbA 1c ), and lipid indices. Although data for urine albumin to creatinine ratio, HbA 1c , and lipid indices were rightskewed, we present the results for these variables on their original scale to assist with interpretation from a clinical perspective. The P values for comparison of these variables are valid estimates, given the asymptotic considerations, on the basis of the relatively large sample size. 16 Models fit to the original laboratory indices determine yearly decline in their native units, whereas models fit using logtransformed eGFR estimate their annual percentage decline. No serious violations of model assumptions were found on examination of the distribution of residuals. The function lmer (from the R package lmerTest, which calculates P values for fixed effects using Satterthwaite approximations) was used to fit and test the models. 17, 18 Interactions between CKD subgroup and DRC attendance were tested via likelihood ratio tests.
For each participant, the first available laboratory result from 
RESULTS
Of the 200 eligible participants, 43 (21.5%) had T1D alone, 127 (63.5%) had T2D alone, and 30 (15.0%) were defined as having DM with an additional CKD etiology. Within the latter group, 1 individual (3.3%) had T1D, and 29 (96.7%) had T2D. The additional CKD etiologies consisted of the following: atherosclerotic renovascular disease (n¼14; 46.7%); hypertensive nephropathy (n¼7; 23.3%); interstitial renal disease (n¼3; 10.0%); obstructive nephropathy (n¼3; 10.0%); glomerulonephritis (n¼2; 6.7%) (1 each with IgA nephropathy and membranous nephropathy); and autosomal-dominant polycystic kidney disease (n¼1; 3.3%).
Regarding ethnicity, 2 patients (1.0%) were Asian, and 1 (0.5%) was black. The total number of attendance occasions at DRC varied, with 52 patients (26.0%) attending once, 36 (18.0%) attending twice, 29 (14.5%) attending 3 times, and 83 (41.5%) attending 4 or more times. At first DRC attendance (Table 2) , no significant differences in blood pressure or smoking status were observed across the 3 subgroups. Body mass index was higher in those with either T2D alone or an additional CKD etiology compared with those who had T1D (P<.001). The group with T1D alone had a higher mean eGFR (P¼.01) and a higher median albuminuria level than the other groups (P¼.02). Higher levels of HbA 1c (P<.001), total cholesterol (P<.001), and low-density lipoprotein cholesterol (P¼.002) were also observed in the group who had T1D alone. Table 3 presents additional clinical characteristics of the study cohort during longitudinal follow-up. Hypertension and peripheral arterial disease were more prevalent in those who had T2D and those who had an additional CKD etiology (P<.001 and P¼.04, respectively), whereas diabetic retinopathy was more prevalent in those who had T1D and T2D (P¼.001). Usage of renin-angiotensinaldosterone system inhibitors was highly prevalent, with 156 (78.0%), 100 (50.0%), and 53 (26.5%) individuals, respectively, on a regimen of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and dual renin-angiotensin-aldosterone system blockade at some point during follow-up. No difference was found in the usage rates of Kruskall-Wallis test was used to assess for variation across the CKD subgroups in continuous variables that were not normally distributed. The number of DRC visits and the duration of renal functional follow-up during the study period are presented in Table 4 . The median (interquartile range) number of DRC visits was similar across all CKD subgroups: 3.0 (6.0) for T1D alone, 3.0 (4.0) for T2D alone, and 3.0 (3.0) for DM with an additional CKD etiology (P¼.84). Median (interquartile range) duration of renal functional follow-up for the total cohort was 7.4 (3.4) years overall: 2.7 (3.2) years before and 3.7 (3.6) years after first DRC attendance.
Annual absolute and percentage changes in CKD-EPI eGFR before vs after index DRC visit were (in mL/min in BSA per year and %/year, respectively): À1.59 vs À3.10 (P¼.31) and À1. 22 
DISCUSSION
This study provides insight into potentially selective renal benefits of a DRC intervention as determined by CKD etiology. The group we describe is larger than previously reported DRC cohorts, [6] [7] [8] [9] [10] and this study is the first to compare trends in renal functional and metabolic indices among those with CKD adjudged to be caused by T1D, T2D, or DM with an additional established etiology.
Previous studies of the impact of DRCbased care differ from the current report in their focus on primarily severe DKD. [7] [8] [9] [10] In absolute terms, individuals who had T2D or DM with additional CKD etiologies in this cohort had statistically significant reductions in the rate of renal functional decline after DRC attendance. This finding suggests that previously reported benefits of DRC attendance for patients who have rapidly progressing DKD also may apply to those who have moderate rates of eGFR decline. However, expressing ongoing renal functional loss as a percentage of existing renal function rather than as an absolute rate of decline may result in an exaggerated perception of benefit from an intervention. 19 In this study, the subgroup with T2D alone experienced stable but persistent proportionate decline in renal function of roughly 10% annually after DRC attendance. This finding suggests that the reduction observed in the absolute rate (mL/min in BSA per year) of renal functional decline after DRC attendance in this subgroup can be ascribed, at least in part, to a slowing effect that occurs as the finite value of eGFR approaches zero. Nonetheless, the lack of an acceleration in the proportionate rate of renal functional deterioration, despite the advancement of DKD, may be considered a positive outcome of DRC attendance for this subset of patients. 20 In contrast, those who had additional CKD etiologies experienced decline in rate of renal functional loss, measured as either an absolute or proportionate change, after DRC attendance. Therefore, these patients plausibly experienced a benefit from encountering nephrology-led diagnosis and management at the DRC earlier in their CKD course than might otherwise have been the case. Although individuals with additional CKD etiologies have been excluded from previous studies examining DRC interventions, 6-10 biopsy-based studies have consistently found that a substantial proportion of patients with diabetes and CKD have one or more nonediabetes-related kidney diseases. 21 The trend toward acceleration in the rate of renal functional decline after DRC attendance in those with T1D was an unexpected finding. The mean CKD-EPI eGFR was 14.5 mL/min per BSA higher at the index DRC visit in the group who had T1D alone compared with those who had T2D. However, certain predictors of renal functional decline were more prevalent in those with T1D. 22 For example, the T1D group had DM for 14 years longer than their T2D counterparts. Additionally, patients with T1D had higher time-averaged HbA 1c level, total cholesterol level, and low-density lipoprotein cholesterol parameters, had a greater degree of proteinuria, and were more likely to be active smokers when referred. The discordant trajectory in renal function after DRC attendance in those who had T1D compared with those who had T2D may also be related to recognized differences in the pathophysiology of type 1 and type 2 diabetic kidney disease. 23 Hyperglycemia is frequently more severe and of longer duration in type 1 diabetic kidney disease. 23 Recently, epigenetic changes in kidney cells have been identified as a mechanism by which periods of poor glycemic control may perpetuate ongoing renal functional losses. [24] [25] [26] Although patients with T1D experienced annual decline in HbA 1c both before and after DRC attendance, the degree of decline lessened after DRC attendance, and baseline HbA 1c values at the index DRC visit were much higher in this subgroup. Thus, adverse metabolic memory may have contributed to ongoing renal functional losses in those with T1D, despite improvement in glycemic control. In addition, some patients with T1D may have transitioned from the hyperfiltration phase of DKD to a period of persistent eGFR decline after DRC attendance, 27 accounting for some of the paradoxical worsening in renal function observed in this subgroup. Nevertheless, mean CKD-EPI eGFR was 61.0 mL/min per BSA at first DRC attendance, and annual trajectory in renal function was negative before DRC attendance for the T1D subgroup, suggesting that the influence of the hyperfiltration phase of DKD on the observed renal functional changes in this subgroup was likely modest.
Current treatment of DKD is relatively limited and focuses on minimizing the rate of renal functional loss rather than reversing it. 28 However, an increasing number of novel therapies for DKD are in various stages of development, 29, 30 with recent endeavors particularly focusing on inflammatory pathways in DKD. 31 In addition, emerging evidence reveals that hypoglycemic agents of the sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide 1 receptor agonist classes exert reno protective benefits through hemodynamic alterations and modulation of inflammation. [32] [33] [34] A further benefit of DRCs may be that their referral criteria often broadly match characteristics of the target populations for novel therapeutic interventions in DKD and may facilitate the enrollment of higherrisk patients into clinical trials.
The observational nature of this study limits the conclusions that can be drawn regarding the direct role of decisions made at the DRC in the benefits observed. 35 The lack of a control group of patients who have DKD being managed in a general DM clinic also limits the strength of our inferences regarding the impact of DRC attendance on rate of eGFR decline. The multifactorial nature of CKD is often difficult to tease apart definitively without histopathological information. 36 However, despite the lack of biopsy proof of diabetic nephropathy for most of the patients in this cohort, we succeeded in creating 3 distinct CKD etiological groups through the use of strict criteria to define additional CKD etiologiesd groupings that are supported by the higher degree of albuminuria in the T1D and T2D subgroups compared with those categorized as having DM with additional CKD etiologies. 37 The predominance of white patients in our outpatient cohort limits the applicability of our findings to adults from other racial and ethnic backgrounds. The relatively small sample size limits statistical power. However, analyses of trends in renal function were made on the basis of a median of 28 eGFR values over a median of 7.4 years of longitudinal follow-up per participant. Owing to limitations in our electronic medical record system, start and stop dates for individual medications could not be recorded. Instead, the data given on medication usage are intended to provide an overview of various medication class exposures during study follow-up. Blood pressure measurements taken before first DRC attendance were not available for comparison with posteDRC attendance values, further limiting interpretation of the clinical determinants of the renal functional trends.
CONCLUSION
After DRC consultation, the absolute rate of eGFR decline was similar for those who had T1D but slower for those who had T2D and DM with additional CKD etiologies. Percentage loss of renal function was higher in those who had T1D, similar in those who had T2D, and lower in those with additional CKD etiologies. Our results provide evidence that, for patients who have T2D and documented stage 3 CKD (eGFR < 60 ml/min per BSA), medical care may be effectively optimized for renal functional preservation in an outpatient setting involving collaboration between diabetologists and nephrologists. We also conclude that DRC referral should not be restricted to those who have rapid renal functional decline, and it may provide particular benefit to diabetic patients who have additional CKD etiologies.
